Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of QPI-1002 to prevent delayed graft function after older deceased-donor kidney transplant
NL-OMON43248Phase 3Withdrawn
- Sponsor
- Quark Pharmaceuticals
- Start
- Sep 2016
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in delayed graft function (DGF) and Kidney allograft dysfunction comparing QPI-1002 with Placebo (2 arms). Primary endpoint: Delayed graft function severity through Day 30. Planned start Sep 2016; status: withdrawn.
02
Drugs
teprasiran
03
Conditions
delayed graft function (DGF)Kidney allograft dysfunction
Beyond the preview
Go deeper on NL-OMON43248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43248.